Saturday 17 October 2026
Export ENLV’s income statement to Excel — free account
Enlivex Ltd.
ENLV Healthcare Biotechnology
In the quarter to June 2026, EPS grew 5,185.1% and free cash flow grew 35.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.21
0.01
−4.55%
Follow ENLV
| Older periods | Jun '25 | Sep '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(55.02%) | (57.64%) | 126.17% | 159.77% | |
| (48.07%) | (50.07%) | 104.94% | 127.16% | ||
ROIC |
0.00% | 0.00% | (4.78%) | (5.85%) | |
Return on Tangible Assets |
(70.85%) | (75.17%) | 71.23% | 84.16% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(7.92) | (7.46) | (3.44) | 0.00 | |
Free Cash Flow |
(12.59) | (11.96) | (10.48) | — | |
Capital Expenditures |
(0.07) | (0.09) | (0.07) | — | |
| Other line items | |||||
Cash ROIC |
(32.65%) | (33.52%) | (0.29%) | 0.00% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | (0.14) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Interest Coverage |
59.77 | — | — | (39.32) | |
Operating CF/Net income |
0.96 | 0.93 | (0.01) | 0.00 | |
Depreciation/Fixed assets |
0.76 | 0.68 | 0.92 | 0.00 | |
Capex/Depreciation |
(0.19) | (0.30) | (0.20) | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.88) | (7.40) | (3.42) | 0.00 | |
Capex per Share |
(0.04) | (0.05) | (0.02) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026